Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma

He,Guoping; Zhao,Baojian; Zhang,Xu; Gong,Rixiang

doi:10.3892/ol.2013.1713

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma

Authors:
- Guoping He
- Baojian Zhao
- Xu Zhang
- Rixiang Gong
View Affiliations

Affiliations: The Center for Reproductive Medicine, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui 230001, P.R. China, Molecular Pathology Center of the General Hospital of the Air Force PLA, Beijing 100081, P.R. China, Department of Thyroid and Breast Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: November 29, 2013 https://doi.org/10.3892/ol.2013.1713
Pages: 439-443

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the prevalence of the BRAF V600E mutation in papillary thyroid carcinoma (PTC) and to determine the correlation between this mutation and indicators of poor prognosis and outcome in patients with PTC. The BRAF V600E mutation status was analyzed in 187 tumor samples using the multiplex allele‑specific PCR method. Univariate and multivariate analyses were performed to investigate the association of the BRAF V600E mutation with clinical features and patient outcome. The sensitivity of the multiplex allele-specific PCR combined with denaturing high‑performance liquid chromatography reached ~1%. The BRAF V600E mutation was observed in 63.6% (119/187) of tumor tissues, predominantly in PTC specimens, and no BRAF mutation was identified in other benign‑type thyroid diseases. The univariate analysis indicated that the BRAF V600E mutation was associated with age, tumor stage and prognosis (P<0.05). In addition, the frequency of the BRAF V600E mutation was significantly different in the central (75.3%) and lateral neck (49.3%) lymph nodes of patients with lymph node metastasis. Multivariate logistic regression analysis showed that the BRAF V600E mutation (HR, 2.471; 95% CI, 1.149-5.312) and lymph node metastasis (HR, 3.003; 95% CI, 1.027-8.771) are independent factors that predict tumor prognosis. Thus, the BRAF V600E mutation is an independent risk factor that may be used to predict thyroid cancer persistence/recurrence.

View Figures

View References

1	Ries LAG, Melbert D, Krapcho M, et al: SEER Cancer Statistics Review, 1975–2005. National Cancer Institute; Bethesda, MD: 2007
2	Schlumberger M and Pacini F: Prognostic factors. Thyroid Tumors. Nucleon Editions; Paris: pp. 111–125. 2003
3	Witt RL: Initial surgical management of thyroid cancer. Surg Oncol Clin N Am. 17:71–91. 2008. View Article : Google Scholar : PubMed/NCBI
4	Kim TH, Park YJ, Lim JA, et al: The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 118:1764–1773. 2012. View Article : Google Scholar : PubMed/NCBI
5	Xing M, Clark D, Guan H, et al: BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol. 27:2977–2982. 2009. View Article : Google Scholar
6	Gong RX, Zhou Y, Luo SH, et al: An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 26:310–313. 2009.(In Chinese).
7	Kebebew E, Weng J, Bauer J, et al: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 246:466–471. 2007. View Article : Google Scholar : PubMed/NCBI
8	Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
9	DeLuca AM, Srinivas A and Alani RM: BRAF kinase in melanoma development and progression. Expert Rev Mol Med. 10:e62008. View Article : Google Scholar : PubMed/NCBI
10	Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI
11	Ball DW: Selectively targeting mutant BRAF in thyroid cancer. J Clin Endocrinol Metab. 95:60–61. 2010. View Article : Google Scholar : PubMed/NCBI
12	Costa AM, Herrero A, Fresno MF, et al: BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf). 68:618–634. 2008. View Article : Google Scholar
13	Howell GM, Carty SE, Armstrong MJ, et al: Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol. 18:3566–3571. 2011.
14	Bollag G, Tsai J, Zhang J, et al: Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 11:873–886. 2012. View Article : Google Scholar : PubMed/NCBI
15	Tufano RP, Teixeira GV, Bishop J, et al: BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore). 91:274–286. 2012. View Article : Google Scholar
16	Henderson YC, Shellenberger TD, Williams MD, et al: High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res. 15:485–491. 2009. View Article : Google Scholar : PubMed/NCBI
17	Alzahrani AS and Xing M: Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND. Endocr Relat Cancer. 29:13–22. 2013. View Article : Google Scholar
18	Bozec A, Dassonville O, Chamorey E, et al: Clinical impact of cervical lymph node involvement and central neck dissection in patients with papillary thyroid carcinoma: a retrospective analysis of 368 cases. Eur Arch Otorhinolaryngol. 268:1205–1212. 2011. View Article : Google Scholar
19	Elisei R, Viola D, Torregrossa L, et al: The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 97:4390–4398. 2012. View Article : Google Scholar
20	O’Neill CJ, Bullock M, Chou A, et al: BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery. 148:1139–1145. 2010.